Phenotype
|
Fish
|
Conditions
|
Figures
|
pharyngeal arch 2 decreased size, abnormal
|
gib1002Tg + MO3-ep300b
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
pharyngeal arch 3-7 decreased size, abnormal
|
gib1002Tg + MO3-ep300b
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
cranial skeletal system development disrupted, abnormal
|
gib1002Tg + MO3-ep300b
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
atrium increased size, abnormal
|
gib1002Tg + MO3-ep300b
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
pharyngeal arch 1 decreased size, abnormal
|
gib1002Tg + MO3-ep300b
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
trunk glioblast foxd3 expression increased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
statoacoustic (VIII) ganglion neurod1 expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
cartilage tissue sox9b expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 5
from Babu et al., 2018
|
cranial ganglion neurod1 expression absent, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
hindbrain neurod1 expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
pectoral fin cartilage sox9a expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 5
from Babu et al., 2018
|
retina neurod1 expression absent, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
head glioblast foxd3 expression increased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
pectoral fin cartilage sox9b expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 5
from Babu et al., 2018
|
peripheral olfactory organ neurod1 expression absent, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
pectoral fin tbx5a expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 5
from Babu et al., 2018
|
glial cell mbpa expression decreased amount, abnormal
|
TU + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 6
from Babu et al., 2018
|
pectoral fin development disrupted, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 8
from Babu et al., 2018
|
pectoral fin aplastic/hypoplastic, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
cranial skeletal system development disrupted, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 1 decreased size, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
pectoral fin development disrupted, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 3-7 aplastic/hypoplastic, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 8
from Babu et al., 2018
|
cranial skeletal system development disrupted, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 1 decreased size, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
whole organism has fewer parts of type pectoral fin, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
atrium position, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
pharyngeal arch 2 decreased size, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4,
Fig. 8
from Babu et al., 2018
|
pectoral fin development disrupted, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
eye decreased size, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
pericardium edematous, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
cartilage tissue sox9b expression amount, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 1 decreased size, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4,
Fig. 8
from Babu et al., 2018
|
cartilage tissue sox9b expression decreased amount, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
control
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 2 decreased size, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
atrium increased size, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
cardiac ventricle position, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
cartilage tissue sox9b expression amount, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
cranial skeletal system development disrupted, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4,
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 2 decreased size, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 3-7 aplastic/hypoplastic, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: EC 3.5.1.98 (histone deacetylase) inhibitor
|
Fig. 8
from Babu et al., 2018
|
pectoral fin aplastic/hypoplastic, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4,
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 3-7 aplastic/hypoplastic, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
pectoral fin aplastic/hypoplastic, ameliorated
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
chemical treatment: 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
|
Fig. 8
from Babu et al., 2018
|
pharyngeal arch 3-7 decreased size, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|
heart looping disrupted, abnormal
|
gib1002Tg + MO3-ep300b + MO4-ep300a
|
standard conditions
|
Fig. 4
from Babu et al., 2018
|